The private-payer biosimilar gap is the unclaimed margin
Public switching is effectively nationwide. Private plans are still paying originator prices on the same molecules — the most actionable structural inefficiency in the Canadian channel right now.
All ten provinces and two territories have implemented biosimilar transition policies for their public drug plans (B.C. alone reports 40,000+ patients transitioned and $732M+ saved over five years), while private drug plans use biosimilars at a rate roughly 30% lower than public plans.
Canada has, almost without anyone outside the channel noticing, completed one of the most aggressive biosimilar-transition programs in the world. All ten provinces and two territories have implemented biosimilar transition policies for their public drug plans, and the savings are not marginal: British Columbia alone reports more than 40,000 patients transitioned and over $732 million saved over five years. On the public side, the switch is essentially done.
Create a free account to read the full interpretation.
You’ve reached the part where The Indication earns its name — the read on distribution, reimbursement timing, and channel strategy. It’s free to finish: sign in or create an account to keep reading every analysis in full.